Brief: SEED Therapeutics Completes $30 Million Series A-3 Financing
23/09/2025 12:07
Sept 23 (Reuters) - Eisai Co Ltd 4523.T: SEED THERAPEUTICS COMPLETES $30 MILLION SERIES A-3 FINANCING SEED THERAPEUTICS : ANTICIPATES ENTERING FIRST-IN-HUMAN CLINICAL TRIALS OF ST-01156 IN Q1 2026 SEED THERAPEUTICS: RECEIVED $60 MILLION IN EQUITY, AND COLLABORATION UPFRONT & MILESTONE PAYMENTS COMBINED, FROM PARTNERSHIPS WITH ELI LILLY & EISAI Source text: ID:nGNX5WPwGR Further company coverage: 4523.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China